The Laboratory Role in anti-TNF Biological Therapy Era

Mariapaola Marino, Annunziata Stefanile, Cecilia Napodano, Krizia Pocino, Antonella Di Pino, Gian Ludovico Rapaccini, Umberto Basile, Valentina Grossi, Francesca Gulli, Maria Infantino, Maurizio Benucci, Francesca Li Gobbi, Arianna Damiani, Mariangela Manfredi, Valerio Basile

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)


Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic–therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient’s group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.
Lingua originaleEnglish
pagine (da-a)1-16
Numero di pagine16
RivistaImmunological Investigations
Stato di pubblicazionePubblicato - 2019


  • TNF
  • adalimumab
  • anti-TNF drugs
  • certolizumab
  • immunogenicity


Entra nei temi di ricerca di 'The Laboratory Role in anti-TNF Biological Therapy Era'. Insieme formano una fingerprint unica.

Cita questo